MacroGenics
MGNX
133 hedge funds and large institutions have $165M invested in MacroGenics in 2022 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 53 increasing their positions, 33 reducing their positions, and 32 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 33
29% more call options, than puts
Call options by funds: $93K | Put options by funds: $72K
3.76% more ownership
Funds ownership: 98.34% → 102.1% (+3.8%)
8% less funds holding
Funds holding: 144 → 133 (-11)
28% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 32
69% less capital invested
Capital invested by funds: $528M → $165M (-$363M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$5.93M |
| 2 |
Millennium Management
New York
|
+$5.74M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$5.17M |
| 4 |
Renaissance Technologies
New York
|
+$4.44M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$4.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$53.8M |
| 2 |
State Street
Boston,
Massachusetts
|
-$12M |
| 3 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$2.53M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.51M |
| 5 |
Rafferty Asset Management
New York
|
-$1.83M |
MGNX Hedge Fund Activity: Q2 2022 in Review
133 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in MacroGenics (MGNX) for Q2 2022, worth a combined $165M — down 69% from $528M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of MGNX and 23 opened new positions — a net loss of 9 holders — while 33 trimmed existing stakes and 53 added.
The largest buyer was Armistice Capital, adding an estimated $5.93M. The largest seller was RA Capital Management, exiting entirely with an estimated $53.8M sold.
- 133 institutional investors held MacroGenics (MGNX) as of Q2 2022, down from 144 in Q1 2022.
- Funds reported $165M of MacroGenics stock for Q2 2022, down 69% quarter-over-quarter.
- 23 funds opened new MacroGenics positions in Q2 2022 and 32 closed out, a net change of -9 holders.
- The largest MacroGenics buyer in Q2 2022 was Armistice Capital, an estimated $5.93M added.
- The largest MacroGenics seller in Q2 2022 was RA Capital Management, an estimated $53.8M sold.
Based on aggregated 13F filings for Q2 2022.